Cognitive, Mood & Stress
Selank, Semex and its combination FDA Status
Two substances, two different regulatory records
Semax was considered by FDA’s Pharmacy Compounding Advisory Committee on 24 July 2026. Selank has never been reviewed by that committee at all. Neither appears on either Bulks List, in either nominations document, or on 21 CFR 216.24. This page sets out what we checked in September 2026, what each source settles.
Semax has an advisory history. Selank has none.
On 24 July 2026 FDA’s Pharmacy Compounding Advisory Committee considered Semax free base and Semax acetate for possible inclusion on the 503A Bulks List. FDA’s own briefing document for that meeting stated that “FDA is proposing that semax (free base) and semax acetate NOT be included on the 503A Bulks List.” Trade press reports the committee then voted to recommend inclusion. Selank was not on the agenda for that meeting or any other we located.
Nothing was added to any list. A committee recommendation does not amend the regulation. The 503A Bulks List sits at 21 CFR 216.23 and changes only by notice-and-comment rulemaking. We read it on 5 September 2026: six substances, and semax is not among them.
Neither substance appears on the 503A Bulks List, the 503B Bulk Drug Substances List, the 503A nominations document updated 14 May 2026, the 503B nominations document updated 21 March 2025, 21 CFR 216.24, or FDA’s drug shortage database. Both sit in the nominated-but-withdrawn table on FDA’s safety-risks page, content current 22 April 2026.
HOW WE SUPPORT CLINICS
Phoenix Meds Regulatory Support Model
Our support in this category is built around the one thing it gets wrong: an advisory vote is being read as a decision.
A Vote Separated From a List
The committee recommended. FDA has not acted. The regulation at 21 CFR 216.23 still holds six substances and semax is not one of them. We read that text rather than the coverage of the meeting.
Evaluated Use Recorded
FDA evaluated semax for cerebral ischemia, migraine and trigeminal neuralgia. Those are the conditions in the briefing document. We record the use FDA actually assessed, because it is rarely the use the substance is being sold for.
FDA’s Own Position Quoted
The agency proposed against inclusion and gave its reasons in writing. A summary that reports the vote without the briefing document has reported half the meeting. We carry both.
Foreign Registration Named, Then Refuted
Both substances were developed in Russia and are dispensed there. No foreign registration creates a United States compounding basis. We say so in the same breath as we name it, because suppliers lead with it.
Each Half of a Blend Read Alone
Semax and Selank are sold as one item. Their federal records are not alike: one has an advisory history, the other has nothing. We read each component against the sources and report them separately.
Rulemaking Watched, Not Predicted
If FDA moves on the July recommendation it will do so by notice-and-comment rulemaking. We watch the Federal Register and the regulation. We do not estimate when, and we do not tell a clinic it is coming.
Phoenix Meds Inc. provides independent regulatory tracking and compliance analysis for licensed healthcare facilities. We are not a pharmacy, outsourcing facility, clinic, prescriber, wholesale distributor, or legal counsel, and we do not dispense, broker, or distribute prescription pharmaceuticals. Our role is to monitor the federal record, document what primary sources establish on the date reviewed, and provide clinics with objective regulatory context before clinical or procurement commitments are made. This page serves two specific purposes: it details the federal regulatory standing of Semax and Selank individually, and it establishes precisely what the July 2026 advisory vote did and did not alter under federal law
Regulatory Support Delivered
Clinic Benefits
This category produces one specific kind bad information, and it arrives looking official.
✓ The briefing document, not the headline
July 2026 coverage says a panel backed six peptides. FDA’s written position on semax was the opposite. Both are true and a clinic needs both.
✓ The right substance Attached to the Vote
Semax was on the agenda. Selank was not. A blend sold as one product does not inherit one component’s advisory history.
✓ Every statement dated
Each line here carries the day we read the source. A supplier summary predating 24 July 2026 cannot be describing that meeting.
✓ Source you can reopen
Every source is linked below with the date checked and what it settles. A compliance lead can repeat the whole check in an afternoon.
✓ Evaluated conditions named
Cerebral ischemia, migraine and trigeminal neuralgia were the conditions before the committee. Knowing that makes most supplier summaries fall apart on sight.
✓ Rulemakin kept apart from recommendation
What would have to happen for 21 CFR 216.23 to change, and the plain fact that it has not happened.
Those apply to record-keeping; they do not establish lawfulness. An FDA establishment registration, state license, or vendor Certificate of Analysis confirms details about the facility or raw material, but none of them satisfies the statutory requirements of Section 503A. Under current federal law, no compounding pharmacy or legal counsel can establish a lawful basis to compound Semax or Selank from bulk active ingredients until the FDA completes formal notice-and-comment rulemaking
Cognition, Mood and Stress in Clinical Practice
Clinics see these presentations constantly: difficulty concentrating, low mood, a persistent stress load that has not responded to the obvious changes. People arrive having read about peptides. The presentations are real and a prescriber’s judgement about how to address them is a matter for the prescriber.
That judgement is a separate question from whether a particular substance may lawfully be obtained. Prescriber discretion is wide. It does not extend to obtaining a substance for which no pharmacy has an identified basis to compound, and the two questions are commonly treated as one. This page addresses only the second.
One distinction matters more here than elsewhere on this site. FDA’s evaluation of semax concerned cerebral ischemia, migraine and trigeminal neuralgia. Those are neurological conditions with defined diagnostic criteria. They are not the same as the concentration and mood presentations this category is marketed around, and nothing FDA reviewed in July 2026 speaks to the latter.
The Two Substances in This Category
Read separately, because their federal records diverge sharply.
Semax: An advisory recommendation FDA had argued against
Semax is a synthetic heptapeptide, developed in Russia and dispensed there. It has never held United States approval. We did not identify an approved US drug product containing it.
What happened on 24 July 2026. FDA’s Pharmacy Compounding Advisory Committee considered Semax free base and Semax acetate for possible inclusion on the 503A Bulks List. While nominators originally proposed Semax for ADHD and nootropic enhancement alongside neurological indications, the FDA screened out the ADHD nomination for lack of evidence and restricted its evaluation of nootropic claims solely to post-stroke recovery. The only conditions formally evaluated before the committee were cerebral ischemia, migraine, and trigeminal neuralgia.
What FDA itself proposed. The agency’s briefing document for that meeting states: “FDA is proposing that semax (free base) and semax acetate NOT be included on the 503A Bulks List.” FDA found the substances “are not well characterized from a physiochemical perspective” and lacked “certain critical characterization data, such as impurities, aggregates, microbial bioburden and/or bacterial endotoxin levels.” On safety it recorded “insufficiently characterized data to support the safety of these substances” with “additional concerns related to potential immunogenicity risk.” On effectiveness it found “insufficient evidence of effectiveness to support the use of semax-related BDSs” for those conditions.
What the committee did. Trade press reports that the committee voted to recommend inclusion, one account giving eight in favour, five against and one abstention. FDA has published no minutes, transcript or vote record for the meeting, so that tally reaches this page through trade reporting rather than a primary source, and we say so rather than dress it up. Accounts of the meeting differ on the exact tallies for other substances, which is a reason to treat all of them as reported rather than established.
What the vote did not do. The committee advises. It does not amend the regulation. The 503A Bulks List lives at 21 CFR 216.23 and is changed by notice-and-comment rulemaking. We read that regulation on 5 September 2026: it contains six substances, none of them semax. Semax is also absent from the 503A nominations document updated 14 May 2026 and from the 503B nominations document updated 21 March 2025, and it is not on the 503B Bulk Drug Substances List or FDA’s drug shortage database.
What the safety-risks page says. Semax appears there under nominated-but-withdrawn, as “Semax (heptapeptide)”, content current 22 April 2026. FDA’s entry reads: “Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.”
Our finding. On the federal sources reviewed in September 2026 we did not identify a 503A or 503B basis permitting semax to be compounded from bulk. The July 2026 recommendation is a real event in the record and we report it as one. It is not a statutory condition, and until FDA acts through rulemaking it does not become one.
Selank: No advisory history at all
Selank is a synthetic heptapeptide, also Russian in origin, also dispensed there, also without United States approval. We did not identify an approved US drug product containing it.
Where it stands. Selank acetate appears in the nominated-but-withdrawn table on FDA’s safety-risks page as “Selank acetate (TP-7)”, content current 22 April 2026. FDA’s entry reads: “Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans.”
Note what that last sentence is and is not. It is a statement that FDA does not have the information. It is not a finding of harm, and it is not a finding of safety either. Nothing should be read into the silence in either direction.
The advisory record. Selank was not on the agenda for the 24 July 2026 meeting. It appears once in that meeting’s briefing document, and only as a reference to a combination product containing a different peptide. We located no Pharmacy Compounding Advisory Committee review of selank on the committee’s calendar.
That absence is worth stating plainly because of what sits next to it. Semax was reviewed and recommended by the committee eight weeks ago. Selank was not reviewed at all. A clinic told that “the FDA panel backed these peptides” has been told something that was never about selank.
Our finding. On the federal sources reviewed in September 2026 we did not identify a 503A or 503B basis permitting selank to be compounded from bulk. It is absent from both Bulks Lists, both nominations documents, 21 CFR 216.24 and the shortage database.
The combination: Semax + Selank
The combination does not appear to qualify for the Section 503A bulk-drug pathway.
Semax and Selank are commonly marketed together under a single trade name. Under Section 503A, however, each active bulk drug substance used in a compounded formulation must independently satisfy the applicable statutory requirements. FDA’s current 503A framework provides pathways based on an applicable USP–NF monograph, status as a component of an FDA-approved drug, or inclusion on FDA’s 503A Bulks List.
Based on the current FDA record, Selank does not appear on the 503A Bulks List, and we have not identified an applicable USP–NF monograph or FDA-approved drug product containing Selank. Accordingly, combining Selank with Semax would not, by itself, provide Selank with a 503A pathway. The eligibility of each bulk substance must be considered independently.
Furthermore, combining Semax and Selank may introduce additional quality and safety concerns, including aggregation and potential immunogenicity. FDA materials have identified aggregation and peptide-related impurities as concerns associated with certain peptide bulk drug substances. These scientific concerns are separate from the statutory question of whether a particular bulk substance qualifies for compounding under Section 503A.
EVIDENCE
The Evidence and What FDA Recorded
Stated separately from status, because the two are different questions.
What the record contains
Both substances have a Russian research literature going back to the 1980s, much of it preclinical and published in Russian. That work provides scientific context, but it carries no regulatory weight under United States drug law. A supplier presenting volume of foreign literature as evidence of U.S. compounding status has conflated research exploration with statutory compliance.
The FDA evaluated the clinical evidence for Semax across three specific neurological conditions (cerebral ischemia, migraine, and trigeminal neuralgia) and determined it was “insufficient… to support the use of semax-related BDSs” for any of them. That is the agency’s formal assessment of the submitted clinical data against defined diagnostic criteria.
What FDA said about the material itself
The characterization findings carry direct implications for patient safety. The FDA recorded that the Semax substances “are not well characterized from a physiochemical perspective” and lacked critical analytical data concerning “impurities, aggregates, microbial bioburden and/or bacterial endotoxin levels.”
Furthermore, the FDA’s safety-risks page records that compounded preparations of both Semax and Selank pose immunogenicity risks for certain administration routes due to peptide aggregation and synthesis-related impurities. When linear peptides aggregate into oligomers, they can act as neo-antigens, potentially triggering anti-drug antibodies or cross-reactive immune responses.
Clinics reviewing vendor documentation should note that standard commercial Certificates of Analysis (CoAs) rarely test for aggregation kinetics, diastereomeric impurities, or validated endotoxin thresholds. More importantly, under Section 503A, a compliant CoA is a necessary baseline requirement alongside Section 510 manufacturer registration, but it cannot cure the absence of a statutory compounding pathway.
On registries, we checked and identified no completed United States clinical trials evaluating either substance for the cognitive, mood, or stress presentations common in outpatient clinical settings.
Why Clinics Have Explored These Peptides
Interest here is easy to account for. The presentations are common, people ask about these compounds by name, and both substances have decades of foreign use behind them that reads as reassurance. The July 2026 vote added something new: for the first time a clinic can point at an FDA advisory committee and say it recommended one of these substances.
That is accurate as far as it goes, which is not as far as it is being taken. The committee recommended. The agency had argued against. Nothing was added to any list, and the conditions under review were not the ones these products are sold for.
None of the above is a recommendation to use these compounds. Any clinical decision, and the responsibility for it, rests with the prescriber and the pharmacy.
Note: A prescription does not by itself give a compounding pharmacy permission to obtain and compound any bulk substance. The pharmacy still needs a valid legal pathway under Section 503A. Also, “off-label” generally refers to using an FDA-approved drug for a use not included in its labeling; it does not itself create a legal pathway for compounding an unapproved bulk substance.
CATEGORY-SPECIFIC TRAPS
Two Questions Specific to This Category
Foreign registration is not a United States pathway
Both substances are registered and dispensed in Russia. That fact gets quoted to clinics as though it settles something. It settles nothing here. Foreign approval is not U.S. approval and creates no U.S. compounding pathway. No foreign regulator has authority over United States compounding, and no foreign approval, monograph, or foreign pharmacopoeial entry creates a legal condition under Section 503A or 503B.
The same applies to pharmacopeias. The 503A monograph condition means an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph. Citing a European or Russian monograph is citing the wrong book. Furthermore, this is not an open question: the FDA officially confirmed in its July 2026 PCAC review that neither Semax nor Selank has an applicable USP–NF monograph, and neither is a component of an FDA-approved drug. That forecloses the first two statutory pathways under Section 503A.
An advisory vote is the easiest thing to misdescribe
Watch for four common commercial moves: A summary that:
- Reports the committee vote while omitting the FDA briefing document.
- Says “approved” where the record says “recommended.”
- Applies the vote to Selank, even though Selank was not among the substances reviewed.
- Attributes the committee’s review to cognition, focus, or stress when the uses evaluated were cerebral ischemia, migraine, and trigeminal neuralgia.
Each step moves further from the underlying record. Taken together, these changes can turn a limited committee review into a much broader claim that an FDA panel endorsed a “cognitive peptide,” even though the FDA briefing materials do not support that characterization. Furthermore, under Section 502(bb) of the FD&C Act, claiming or implying that a compounded peptide is “FDA-backed” or “FDA-endorsed” makes the product misbranded under federal law.
What to Verify Before Any Sourcing Decision
Against the statutory criteria.
Under Section 503A(b)(1)(A), a bulk drug substance used in compounding must satisfy the applicable statutory criteria. FDA explains that the substance must comply with an applicable USP or NF monograph, if one exists; if no applicable monograph exists, it must be a component of an FDA-approved drug product; or, if neither condition applies, it must appear on FDA’s 503A Bulks List. Bulk drug substances must also be accompanied by a valid Certificate of Analysis and manufactured by an establishment registered with FDA under Section 510.
For Semax, FDA’s July 2026 PCAC materials concluded that the available information weighed against placing Semax free base or Semax acetate on the 503A Bulks List. FDA identified concerns regarding characterization, safety, potential immunogenicity, historical use, and insufficient evidence of effectiveness for the uses evaluated. Those uses were cerebral ischemia, migraine, and trigeminal neuralgia.
Selank should be addressed separately. It was not listed as a substance reviewed at the July 2026 PCAC meeting. FDA’s separate safety materials identify Selank acetate as presenting potential concerns involving aggregation and peptide-related impurities.
Under Section 503B. FDA states that an outsourcing facility generally may not compound a drug product containing a bulk drug substance unless the substance appears on the 503B Bulks List or the compounded drug product appears on FDA’s drug shortage list at the time of compounding, distribution, and dispensing. Bulk substances must also satisfy the applicable CoA, manufacturing, and monograph requirements. Accordingly, the absence of Semax or Selank from the applicable 503B pathway is a separate question from whether a supplier provides a Certificate of Analysis or whether a facility is registered as a 503B outsourcing facility.
On the raw material. Ask for the manufacturer’s Certificate of Analysis and evaluate it against the applicable FDA materials. FDA has identified concerns involving peptide-related impurities and aggregation for both Semax and Selank acetate. A Certificate of Analysis can provide quality information about a particular lot, but it does not by itself establish that the substance qualifies for compounding under Section 503A or 503B.
On the supplier’s account of July 2026. Ask in writing which FDA documents support the supplier’s statement.
If the supplier cites the advisory committee vote, request the FDA briefing document as well.
If the supplier claims Selank was reviewed or endorsed at the July 2026 PCAC meeting, ask where Selank appears in the official agenda or meeting materials.
If the supplier cites cognition, focus, mood, or stress, ask which specific uses FDA identified as being evaluated. For Semax, FDA’s July 2026 meeting materials identify cerebral ischemia, migraine, and trigeminal neuralgia.
These are straightforward ways to compare a commercial statement with the underlying FDA record.
On labeling and intended use. Using language such as “Research Use Only” or “Not for Human Consumption” does not, by itself, determine a product’s intended use. FDA’s June 17, 2026 warning letter to Wholesale Peptide stated that, despite such language, the firm’s website contained claims establishing intended use of the products as human drugs.
On facility registration. A Section 503B registration does not by itself authorize an outsourcing facility to compound any bulk substance. The substance and compounded drug product must still satisfy the applicable Section 503B requirements.
State Requirements
Everything above concerns federal law. State pharmacy boards, medical practice acts, prescribing and dispensing rules and facility requirements apply in addition and never instead. A board may restrict office-use supply, require distributor registration, or take its own position on compounded preparations regardless of the federal picture.
Two points bear on this category in particular. Some states regulate the prescribing of substances marketed for cognitive or psychiatric presentations more closely than the general compounding rules would suggest, and a professional liability policy may exclude claims arising from unapproved drugs. Both are worth checking before a first order rather than after.
Sourcing Coordination Through Phoenix Meds
Sourcing position, September 2026
For Semax and Selank, singly or in combination, we have not identified an applicable federal compounding pathway under Sections 503A or 503B based on the FDA record we reviewed. Where an applicable federal and state-law basis can be independently established for a particular transaction, Phoenix Meds may coordinate sourcing through appropriately licensed pharmacy partners, subject to the pharmacy’s independent review and acceptance. Phoenix Meds does not make a legal determination about whether a particular preparation is lawful. We document the applicable FDA requirements and regulatory record so that the clinic, its pharmacy, and qualified legal or regulatory counsel can assess the position.
If the FDA amends 21 CFR § 216.23 through notice-and-comment rulemaking, acts on the July 2026 advisory recommendation, or issues formal guidance that alters the status of these substances, we will update this page and adjust our sourcing coordination policies accordingly. This page is for regulatory tracking only and it is not medical or legal advice.
Verify This Yourself
FDA — PCAC meeting, 23–24 July 2026 — the substances considered and the use identified for each. Semax on 24 July, for cerebral ischemia, migraine and trigeminal neuralgia. Selank does not appear.
FDA — briefing document, 24 July 2026 meeting — carries the proposal against inclusion and the characterisation, safety and effectiveness findings quoted above.
21 CFR 216.23 — the 503A Bulks List. Six substances; neither of ours. Read 5 September 2026.
21 CFR 216.24 — the separate bar on withdrawn or removed products. Neither is caught by it. Checked September 2026.
FDA — 503B Bulk Drug Substances List — five substances; neither of ours. Shows “Updated August 21, 2023”, content current 16 May 2024.
FDA — substances nominated under section 503A — neither appears in any category. Updated 14 May 2026.
FDA — substances nominated under section 503B — a separate document from the 503A one. Neither appears in any category. Updated 21 March 2025.
FDA — bulk substances that may present significant safety risks — the nominated-but-withdrawn table carrying “Selank acetate (TP-7)” and “Semax (heptapeptide)”, with the entries quoted above. Content current 22 April 2026.
FDA Drug Shortages database — the second 503B route. Neither substance identified. Checked September 2026.
FDA warning letter, 17 June 2026 — Wholesale Peptide, Brooksville FL — intended use established from the firm’s own website despite “research use only” labelling.
21 CFR 201.128 — how intended use is established from the circumstances surrounding distribution.
Related Clinic Resources
Legal & Regulatory Status Overview
How 503A and 503B differ, what the bulks lists are, and how we report a finding rather than a legal conclusion.
Immune Support & Healthy Aging
Epitalon was also before the committee on 24 July 2026, and the same reading applies to that vote.
Gut Health & Inflammation
BPC-157 and KPV were considered on 23 July 2026, again for uses that are not the ones they are sold for.
Sourcing Coordination
How verification-gated coordination works and what we ask before any order.
Disclaimer and regulatory scope:
This page provides regulatory information for licensed clinics, compiled from public FDA materials. It is not medical advice or legal advice, and it is not a determination that any product or preparation is lawful.
Based on the federal sources we reviewed in September 2026, we did not identify an applicable federal compounding pathway under Sections 503A or 503B for compounding Semax or Selank from bulk substances. Semax and Semax acetate were considered by FDA’s Pharmacy Compounding Advisory Committee on July 24, 2026, for potential inclusion on the 503A Bulks List. As of this review, Semax has not been added to the 503A Bulks List. This is our description of the FDA record we reviewed at that time, not a legal conclusion.
State pharmacy laws and medical practice acts may impose additional requirements. For an overview of how Sections 503A and 503B differ and how the applicable bulks lists operate, see our Legal & Regulatory Status Overview. Clinics should work with qualified counsel regarding their state’s requirements.
Phoenix Meds Inc. is not a pharmacy, clinic, prescriber, or medical provider, and we do not dispense. We coordinate sourcing between licensed clinics and licensed pharmacies. The pharmacy or outsourcing facility is responsible for its own compounding, dispensing, and shipping decisions, and clinical decisions remain with the treating prescriber.